Managers’ transactions

June 28, 2023Announcement no. 13

Managers’ transactions

In connection with the completion of BioPorto A/S’ rights issue as described in company announcement no. 12, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them.

1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Ejendomsselskabet Jano ApS
2. Reason for the notification  
a) Position/status Closely associated person to Jan Leth Christensen, member of the Board of Directors of BioPorto A/S
b) Initial notification/amendment Initial notification
3. Details of the issuer  
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)  
a) Description of the financial instrument, type of instrument Identification code Shares   ISIN code DK0062496394 merged with permanent ISIN code DK0011048619 on 27 June 2023
b) Nature of the transaction Purchase (subscription of shares in connection with rights issue)
c) Price(s) and volume(s) Price: DKK 1.00, Volume: 8,000,000
d) Aggregated information
  • Aggregated volume
  • Aggregated price
 N/A
e) Date of the transaction 2023-06-23 5:30 a.m. UTC (7:30 a.m. CEST)
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE
1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name John Patrick McDonough
2. Reason for the notification  
a) Position/status Chair of the Board of Directors of BioPorto A/S
b) Initial notification/amendment Initial notification
3. Details of the issuer  
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)  
a) Description of the financial instrument, type of instrument Identification code Shares   ISIN code DK0062496394 merged with permanent ISIN code DK0011048619 on 27 June 2023
b) Nature of the transaction Purchase (subscription of shares in connection with rights issue)
c) Price(s) and volume(s) Price: DKK 1.00, Volume: 175,000
d) Aggregated information
  • Aggregated volume
  • Aggregated price
 N/A
e) Date of the transaction 2023-06-23 5:30 a.m. UTC (7:30 a.m. CEST)
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE

  

1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Maria Ninfa Medina Saunders
2. Reason for the notification  
a) Position/status Member of the Board of Directors of BioPorto A/S
b) Initial notification/amendment Initial notification
3. Details of the issuer  
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)  
a) Description of the financial instrument, type of instrument Identification code Shares   ISIN code DK0062496394 merged with permanent ISIN code DK0011048619 on 27 June 2023
b) Nature of the transaction Purchase (subscription of shares in connection with rights issue)
c) Price(s) and volume(s) Price: DKK 1.00, Volume: 175,000
d) Aggregated information
  • Aggregated volume
  • Aggregated price
 N/A
e) Date of the transaction 2023-06-23 5:30 a.m. UTC (7:30 a.m. CEST)
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE

  

1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Anthony Paul Pare
2. Reason for the notification  
a) Position/status Chief Executive Officer of BioPorto A/S
b) Initial notification/amendment Initial notification
3. Details of the issuer  
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)  
a) Description of the financial instrument, type of instrument Identification code Shares   ISIN code DK0062496394 merged with permanent ISIN code DK0011048619 on 27 June 2023
b) Nature of the transaction Purchase (subscription of shares in connection with rights issue)
c) Price(s) and volume(s) Price: DKK 1.00, Volume: 160,000
d) Aggregated information
  • Aggregated volume
  • Aggregated price
 N/A
e) Date of the transaction 2023-06-23 5:30 a.m. UTC (7:30 a.m. CEST)
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE
1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Neil Allan Goldman
2. Reason for the notification  
a) Position/status Chief Financial Officer and Executive Vice President of BioPorto A/S
b) Initial notification/amendment Initial notification
3. Details of the issuer  
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)  
a) Description of the financial instrument, type of instrument Identification code Shares   ISIN code DK0062496394 merged with permanent ISIN code DK0011048619 on 27 June 2023
b) Nature of the transaction Purchase (subscription of shares in connection with rights issue)
c) Price(s) and volume(s) Price: DKK 1.00, Volume: 160,000
d) Aggregated information
  • Aggregated volume
  • Aggregated price
 N/A
e) Date of the transaction 2023-06-23 5:30 a.m. UTC (7:30 a.m. CEST)
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE

For investor inquiries, please contact:Tim Eriksen, EU Investor Relations, Zenith Advisory, +45 61 88 77 79, e-mail: investor@bioporto.com

About BioPorto BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

BioPorto’s flagship product, The NGAL TestTM,  is designed to aid in the risk assessment of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The NGAL Test is CE marked and registered in several countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR]. For more information visit www.bioporto.com.

 

Attachment

  • 2023 06 28 - Announcement no. 13
Bioporto A/s (LSE:0JJM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Bioporto A/s.
Bioporto A/s (LSE:0JJM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Bioporto A/s.